Atazanavir/ritonavir vs Efavirenz as the first line of treatment in adults living with HIV
DOI:
https://doi.org/10.11606/issn.1679-9836.v100i1p28-34Keywords:
Antiretroviral Therapy, Effectiveness, Safety, Efavirenz, Atazanavir, HIV, Antiretroviral therapy highly activeAbstract
Introduction: New antiretroviral therapy (ART) regimens for HIV could improve clinical outcomes for patients and to change the natural history of the infection. National and international guidelines currently recommend starting the treatment of infected individuals to prevent the deterioration of the immune system and to control viral replication, and prevention of the transmission of HIV infection. Objectives: to analyze the use of antiretroviral therapy those include Atazanavir/ritonavir (ATV/r) or Efavirenz (EFV) in the first line of treatment for adult patients living with HIV. Material and Methods: a retrospective cohort study between August 2019 to July 2020 and focused on the Clinical Immunology Service/day Hospital of the Instituto de Medicina Integral Prof. Fernando Figueira – IMIP. The data were taken from the records selected at random and recorded in standardized questionnaires with subsequent transcription in computerized spreadsheets. The project was approved by the Human Research Ethics Committee (CEP) of IMIP/PE. The data were transcribed in the Excel program, analyzed on Epi Info™. Results: 131 patients participated in the study using EFV or ATV/r as the third drug in the antiretroviral regimen, 73.3% of whom were EFV patients and 26.7% using ATV/r. Initial viral suppression was observed in 88% (p > 0.05) of patients, regardless of the regimen used. Schemes containing ATV/r showed a prevalence of 47.1% of adverse effects and EFV 52.1% (p < 0.001). Conclusion: The findings of this study suggest that both ATV/r and EFZ showed similar effectiveness when used as a first line of treatment.
Downloads
References
Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. New Engl J Med. 2013;368(3):218-30. https://doi.org/10.1056/nejmoa1110187.
Word Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneve; 2016. Available from: http://www.who.int/hiv/pub/guidelines/keypopulations-2016/en/
Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS. 2010;24(10):1598-601. https://doi.org/10.1097/qad.0b013e32833b61ba
Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy. ANRS VISCONTI Study. PLoS Pathogens. 2013; 9(3):e1003211. https://doi.org/10.1371/journal.ppat.1003211
Tran BX, Fleming M, Do HP, Nguyen LH, Latkin CA. Quality of life improvement, social stigma and antiretroviral treatment adherence: implications for long-term HIV/AIDS care. AIDS Care. 2018;30(12):1524-31. https://doi.org/10.1080/09540121.2018.1510094
Jaiswal J, Singer SN, Lekas HM. Resilience and beliefs in the effectiveness of current antiretroviral therapies among recently disengaged low-income people of color living with HIV. Behav Med. 2019;46(1):75-85. https://doi.org/10.1080/08964289.2019.1570070.
Kalichman S, Mathews C, Banas E, Kalichman M. Alcohol-related intentional nonadherence to antiretroviral therapy among people living with HIV, Cape Town, South Africa. AIDS Care. 2019;31(8):951-7. https://dx.doi.org/10.1080%2F09540121.2019.1587357.
UNAIDS Data 2018: Latin America - Country tables. Geneva: UNAIDS; 2019. Available from: https://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf.
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. EUA; 2019. Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines.
Brasil. Ministério da Saúde. Secretaria de Vigilancia em Saude. Departamento de Vigilancia, Prevencao e Controle das Infecções Sexualmente Transmissiveis do HIV/Aids e das Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Adultos. Brasília: Ministério da Saúde; 2018. Disponível em: http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos.
Scott MH, Michael SS, Mauro S, Julio SGM, Robert TS, Donna MJ, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA. 2006;296(7):827-43. https://doi.org/10.1001/jama.296.7.827.
Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25(18):2301-4. https://doi.org/10.1097/qad.0b013e32834cdb71.
Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013;207(9):1359-69. https://doi.org/10.1093/infdis/jit043.
Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Foods and Drug Administration’s Adverse Event Reporting System. AIDS. 2007;21(9):1215-8. https://doi.org/10.1097/qad.0b013e32813aee35.
Hamada Y, Nishijima T, Watanabe K, Komatsu H, Tsukada K, Teruya K, et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis. 2012;55(9):1262-69. https://doi.org/10.1093/cid/cis621.
Rakotondravelo S, Poinsignon Y, Borsa-Lebas F, de la Blanchardière A, Michau C, Jantzem H, et al. Complicated atazanavir-associated cholelithiasis: a report of 14 cases. Clin Infect Dis. 2012;55(9):1270-2. https://doi.org/10.1093/cid/cis620.
Fauci AS, Longo DL, Hauser SL, Jameson JL, Loscalzo J. Harrison Medicina interna. 19a ed. Porto Alegre: Artmed; 2017. v.1.
Bristol-Myers Squibb. Sustiva package insert. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020972s049-021360s038lbl.pdf.
Abdelhady AM, Shugg T, Thong N, Lu JB, Kreutz Y, Jaynes HA, et al. Efavirenz inhibits the human ether-a-go-go related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers. J Cardiovasc Electrophysiol. 2016;27(10):1206-13. https://doi.org/10.1111/jce.13032.
World Health Organization (WHO). International statistical classification of health problems. 10th rev. Geneva; 2010. Disponível em: www.who.int/classifications/icd/en.
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais. Critérios de definição de casos de AIDS em adultos e crianças. Brasília (DF): Ministério da Saúde; 2018. Disponível em: http://www.aids.gov.br/pt-br/node/57787.
Brasil. Ministério da Saúde. Boletim Epidemiológico HIV/Aids. Brasília: Secretaria de Vigilância em Saúde; 2020. Disponível em: http://www.aids.gov.br/pt-br/pub/2020/boletim-epidemiologico-hivaids-2020.
Pernambuco. Secretaria Estadual de Saúde. Secretaria de Vigilância em Saúde. Boletim Epidemiológico HIV/Aids de PE - situação epidemiológica da infecção pelo HIV em Pernambuco. Recife; 2017. Disponível em: http://portal.saude.pe.gov.br/sites/portal.saude.pe.gov.br/files/boletim_hiv_aids-pe_2017.pdf.
Galli L, Spagnuolo V, Bigoloni A, Monforte AD, Montella F, Antinori A, et al. Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. J Antimicrob Chemother. 2016;71(6):1637-42. https://doi.org/10.1093/jac/dkw031.
Horberg M, Klein D, Hurley L, Silverberg M, Towner W, Antoniskis D, et al. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008;9(6):367-74. https://doi.org/10.1310/hct0906-367.
Amariles P, Galindo J, Mueses-Marín HF, Castañeda C. Efectividad y seguridad del esquema genérico lamivudina/tenofovir y efavirenz en pacientes con VIH/SIDA naïve: estudio fase IV no aleatorizad. Cali-Colombia 2012-2014. Rev Chilena Infectol. 2019;36(1):32-40. http://dx.doi.org/10.4067/S0716-10182019000100032.
Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV. 2016;3(11):e510-e520.https://doi.org/10.1016/S2352-3018(16)30091-1.
Kindie E, Anteneh ZA, Worku E. Time to development of adverse drug reactions and associated factors among adult HIV positive patients on antiretroviral treatment in Bahir Dar City, Northwest Ethiopia. PloS One. 2017;14(8):e0221608. https://doi.org/10.1371/journal.pone.0189322.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 José Kayque Neves, Cláudia Menezes, Rodrigo Serafim, Marina Gabriella Pereira de Andrada Magalhães, Edvaldo Souza
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
